MURA实时信号 | 通过Getagraph.com最大化利润

购买 107484 min ago

@ $4.55

发出时间: 15 Feb 2024 @ 01:08

回报率: -21.32%

上一信号: Feb 14 - 22:34

上一信号: 出售

回报率: -0.44 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer...

Stats
今日成交量	95 645.00
平均成交量	246 542
市值	60.58M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-2.66 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00800 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Cuss Francis M	Buy	15 021	Stock Option (right to buy)
2023-12-14	Jackson Scott Thomas	Buy	15 021	Stock Option (right to buy)
2023-12-14	Hickey Benjamin	Buy	15 021	Stock Option (right to buy)
2023-12-14	Cutler Adam D.	Buy	146 452	Stock Option (right to buy)
2023-12-14	Cutler Adam D.	Buy	78 859	Ordinary Shares

INSIDER POWER
100.00
Last 10 transactions
Buy: 353 823 \| Sell: 0

音量相关性

長: -0.22 (neutral)

短: -0.30 (neutral)

Signal:(46.036) Neutral

Mural Oncology plc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Mural Oncology plc 相关性 - 货币/商品

0.06
( neutral )

0.19
( neutral )

0.00
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.21
( neutral )

Mural Oncology plc 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.57M (0.00 %)
EPS:	$-12.43

FY	2023
营收:	$0
毛利润:	$-2.57M (0.00 %)
EPS:	$-12.43

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-11.99

Financial Reports:

No articles found.

Mural Oncology plc

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.